- Home
- SEGG vs CALC Comparison
SEGG vs CALC Comparison
Compare SEGG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | CALC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 19.1M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SEGG | CALC |
|---|---|---|
| Price | $2.58 | $0.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $20.00 | $10.00 |
| AVG Volume (30 Days) | ★ 375.5K | 281.0K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,779,057.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.46 |
| 52 Week High | $7.61 | $7.20 |
Technical Indicators
Market Signals| Indicator | SEGG | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 39.07 |
| Support Level | $0.76 | $0.52 |
| Resistance Level | $2.58 | $0.77 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 32.82 | 4.80 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is operated as a single-reporting unit focused on its lottery and gaming platform, and its organizational structure, internal reporting systems, and resource allocation processes were aligned accordingly.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.